Prothena
Prothena's revenue fell 92.8% to $10 million in fiscal 2025. Its operating margin was −2,216.4%, down from −114.4% a year earlier. The diluted share count rose 0.1%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Prothena does
Prothena is a clinical-stage biotechnology company based in Ireland. It develops treatments for diseases caused by misfolded proteins, including Parkinson's disease, Alzheimer's disease, ATTR amyloidosis with cardiomyopathy (a rare, fatal disease in which misfolded proteins build up in the heart) and ALS. It has no approved products.
Its active clinical programs are all partnered with large drug companies. Prasinezumab is in a Phase 3 trial for early Parkinson's disease with Roche. Coramitug is in a Phase 3 trial for ATTR cardiomyopathy run by Novo Nordisk. BMS-986446 is in a Phase 2 trial for early Alzheimer's disease run by Bristol Myers Squibb, and PRX019 is in a Phase 1 trial run by Prothena as part of a partnership with Bristol Myers Squibb.
Its early-stage research includes a technology called CYTOPE, meant to reach disease targets inside cells, and preclinical work on PRX012, a wholly-owned antibody for Alzheimer's disease. It says it is looking for research collaborations and licensing deals with large drug companies. As of December 31, 2025, it had 67 employees, 36 of them in research and development.
Its biggest risks, as it describes them
- It expects to keep losing money and may never sustain profitability.
- It needs more capital, and may not be able to raise it.
- It depends on partners such as BMS, Roche and Novo Nordisk to carry its drug candidates forward.
- Clinical trials may be delayed or fail, and regulators may not approve its drug candidates.
- It must keep and attract key staff, and partners may want assurance of its stand-alone financial strength.
Income statement
Prothena lost money in fiscal 2025: a net loss of $244 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 579 | 710 | 619 | 471 | 308 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 17.5x | 14.3x | 11.2x | 10.0x | 7.7x |
| Quick ratio | 17.5x | 14.3x | 11.2x | 10.0x | 7.7x |
Cash flow
Free cash flow is cash from operations minus capital expenditure. The SEC's structured data for Prothena's filings doesn't give both for any year, so free cash flow is left out.
Projections
Project Prothena's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Prothena says to expect
- Full year 2026: cash used and year-end cash
The Company continues to expect its full year 2026 net cash used in operating and investing activities to be $18 to $23 million and to end the year with approximat ely $259 million (midpoint) in cash, cash equivalents and restricted cash.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $7.7 million of Prothena shares on the open market, and 2 insiders sold $135,926, all of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 17, 2026 | William P Scully10% owner | Bought | 50,000 | $8.09 | $404,680 | Form 4 |
| Sep 29, 2026 | William P Scully10% owner | Bought | 162,000 | $8.68 | $1.4 million | Form 4 |
| Sep 28, 2026 | William P Scully10% owner | Bought | 103,500 | $8.60 | $890,100 | Form 4 |
| Sep 18, 2026 | William P Scully10% owner | Bought | 100,000 | $8.43 | $843,000 | Form 4 |
| Sep 2, 2026 | William P Scully10% owner | Bought | 27,000 | $9.47 | $255,690 | Form 4 |
| Aug 20, 2026 | William P Scully10% owner | Bought | 50,000 | $8.79 | $439,500 | Form 4 |
| Aug 7, 2026 | William P Scully10% owner | Bought | 37,500 | $8.62 | $323,250 | Form 4 |
| Jul 29, 2026 | Michael John IsaacsGeneral Counsel & Company Sec. | Sold plan | 8,386 | $8.47 | $71,029 | Form 4 |
| Jul 29, 2026 | Anne Evans KingstonChief Strategy Officer | Sold plan | 7,662 | $8.47 | $64,897 | Form 4 |
| Jun 16, 2026 | William P Scully10% owner | Bought | 20,000 | $7.90 | $158,000 | Form 4 |
| Jun 11, 2026 | William P Scully10% owner | Bought | 125,000 | $8.17 | $1.0 million | Form 4 |
| Jun 4, 2026 | William P Scully10% owner | Bought | 50,000 | $9.31 | $465,500 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | — | — | — |
| Altman Z'' | 3.42 | 5.27 | −5.98 |
| Accruals ratio | −1.8% | 4.5% | −18.4% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Fail |
| Cash from operations exceeds net income | Pass | Fail | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Pass | Fail |
| F-score | — | — | — |
Compare
Put Prothena side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Prothena | FY25 | −92.8% | −2,216.4% | — | — | — | — | |
| Taysha Gene Therapies | FY25 | 17.3% | −1,130.7% | −960.1% | — | — | 4 | Compare |
| Janux Therapeutics | FY25 | −5.5% | −1,576.7% | −832.8% | — | — | — | Compare |
| Curis | FY25 | −13.4% | −60.5% | — | — | — | 3 | Compare |
| Alpha Cognition | FY25 | — | −221.7% | −202.3% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 1 | 28 | 1 | 1 | 1 | 201 | 54 | 91 | 135 | 10 |
| Revenue growth | −34.4% | 2,508.4% | −96.5% | −14.8% | 4.8% | 23,414.3% | −73.1% | 69.5% | 47.9% | −92.8% |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Research and development | 120 | 134 | 101 | 51 | 75 | 82 | 136 | 221 | 222 | 135 |
| Operating income | −160 | −155 | −159 | −86 | −113 | 72 | −132 | −191 | −155 | −215 |
| Net income | −160 | −153 | −156 | −78 | −111 | 67 | −117 | −147 | −122 | −244 |
| Diluted EPS (US$) | −4.66 | −4.07 | −3.93 | −1.95 | −2.78 | 1.38 | −2.47 | −2.76 | −2.27 | −4.53 |
| Diluted shares (millions) | 34 | 38 | 40 | 40 | 40 | 48 | 47 | 53 | 54 | 54 |
| Cash flow | ||||||||||
| Cash from operations | −116 | −131 | −28 | −53 | −80 | 93 | −109 | −134 | −150 | −164 |
| Capital expenditure | — | — | — | — | — | — | — | — | — | — |
| Free cash flow | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 25 | 27 | 27 | 24 | 22 | 25 | 31 | 41 | 46 | 38 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 387 | 418 | 428 | 376 | 295 | 579 | 710 | 619 | 471 | 308 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | — | — |
| Total assets | 460 | 496 | 499 | 419 | 333 | 609 | 758 | 696 | 547 | 327 |
| Total liabilities | 95 | 89 | 176 | 146 | 149 | 143 | 136 | 135 | 60 | 46 |
| Shareholders' equity | 365 | 407 | 323 | 273 | 184 | 466 | 622 | 561 | 487 | 280 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | −15,121.8% | −564.2% | −16,634.0% | −10,527.9% | −13,216.2% | 35.9% | −244.1% | −209.1% | −114.4% | −2,216.4% |
| Net margin | −15,176.1% | −556.8% | −16,297.9% | −9,542.6% | −13,029.8% | 33.4% | −216.9% | −160.9% | −90.5% | −2,520.6% |
| Free cash flow margin | — | — | — | — | — | — | — | — | — | — |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | — | — | — | — | — |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | −44.1% | −39.7% | −42.6% | −26.1% | −48.6% | 20.6% | −21.5% | −24.9% | −23.3% | −63.6% |
| Return on assets | −37.9% | −32.0% | −31.3% | −16.9% | −29.6% | 14.2% | −17.1% | −20.2% | −19.7% | −55.9% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |